Pediatric neuromuscular disorders (NMDs) are a group of conditions that affect the functioning of muscles, nerves, and the neuromuscular junction that connects them. They can cause symptoms such as muscle weakness, paralysis, and difficulty with movement. NMDs can range from mild to severe and can be caused by genetic or acquired factors. NMDs can be very difficult to diagnose and treat, as they present differently in different individuals and can be hard to distinguish from other conditions. Most pediatric NMDs are heritable, meaning they can be passed on from parents to children. Examples of inherited NMDs include Duchenne Muscular Dystrophy, Spinal Muscular Atrophy, and Congenital Myasthenia Gravis. Other NMDs can be caused by environmental factors, such as toxins, hypoglycemia, and trauma. Treatment of NMDs often involves physical therapy, medications, and, in some cases, surgery. Common medications used to treat NMDs include acetylcholine esterase inhibitors, which help to reduce muscle weakness, and immunomodulators, which reduce inflammation. Surgery is usually reserved for more serious conditions. It is important to recognize the signs and symptoms of NMDs in children. Early recognition and diagnosis are essential in preventing serious complications and providing effective treatment. Symptoms can include progressive muscle weakness, fatigue, and difficulty walking, running, and speaking. If your child exhibits any of these signs, they should see their doctor right away for diagnosis and treatment.
Title : Perception and individuality in patient cases identifying the ongoing evolution of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Ken Ware, NeuroPhysics Therapy Institute, Australia
Title : Narrative medicine: A communication therapy for the communication disorder of Functional Seizures (FS) [also known as Psychogenic Non-Epileptic Seizures (PNES)]
Robert B Slocum, University of Kentucky HealthCare, United States
Title : Personalized and Precision Medicine (PPM), as a unique healthcare model through biodesign-driven biotech and biopharma, translational applications, and neurology-related biomarketing to secure human healthcare and biosafety
Sergey Victorovich Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Neuro sensorium
Luiz Moutinho, University of Suffolk, United Kingdom
Title : GBF1 inhibition reduces amyloid-beta levels in viable human postmortem Alzheimer's disease cortical explant and cortical organoid models
Sean J Miller, Yale School of Medicine, United States
Title : Traumatic Spinal Cord Injuries (tSCI) - Are the radiologically based “advances” in the management of the injured spine evidence-based?
W S El Masri, Keele University, United Kingdom